Work

Study on the environmental risks of medicinal products

Year: 2013
Type: report
Abstract: Medicinal productsStudy on the risks of environmental effects of medicinal products | 17 This page is left intentionally blank.How do medicinal products behave in the environment?Once in the environment, medicinal products are transformed and transferred among different compartments, depending on the nature of the compounds and the characteristics of the host compartment.There exist voluntary initiatives for monitoring environmental concentrations of medicinal products in some Member States, particularly in the aquatic environment.These data suggest that several medicinal products are detectable in the environment, and their concentration depends on the geographical location, season, local administration practices, and specific environmental factors (T, humidity, etc.).The detected concentrations could be in the range of subng/L levels to more than several µg/L.Medicinal products can degrade biotically or abiotically in soils and water, a process that in general reduces their potency, even if some degradation products might be persistent and thus of concern.For instance, according to a monitoring campaign performed in France, the molecules most frequently found in freshwaters are Carbamazepine (an anti-epileptic medicinal product) and its main metabolite, and Oxazepam (an anxiolytic) which is both a parent product and a metabolite of Action n° 1: Strengthen the promotion of the appropriate use of antimicrobials in all MS Action n° 2: Strengthen the regulatory framework on veterinary medicinal products and on medicated feed.Action n° 3: Introduce recommendations for prudent use in veterinary medicine, including follow-up reports.Action n° 4: Strengthen infection prevention and control in healthcare settings.Action n° 5: Introduce a legal tool to enhance prevention and control of infections in animals in the new Animal Health Law.Action n° 6: Promote, in a staged approach, unprecedented collaborative research and development efforts to bring new antimicrobials to patients.Action n° 7: Promote efforts to analyse the need for new antibiotics into veterinary medicine Action n° 8: Develop and/or strengthen multilateral and bilateral commitments for the prevention and control of AMR in all sectors.Action n° 9: Strengthen surveillance systems on AMR and antimicrobial consumption in human medicine.Action n° 10: Strengthen surveillance systems on AMR and antimicrobial consumption in animal medicine.
Source: HAL
Language: English
Subfield: Pollution
Open Access status: green
OpenAlex ID: W4310374186
Cites:
Cited by: 195
Related to: 10